G Brian Atwood
Affiliations
- Director at Cero Therapeutics Holdings Inc. (CERO), 2025-06-02
- Director at Launch One Acquisition Corp. (LPAA), 2024-07-11
- Director at Atreca Inc. (BCEL), 2023-06-15
- Director at Clovis Oncology Inc. (CLVS), 2021-06-12
- Director at Locust Walk Acquisition Corp. (LWAC), 2021-01-15
- Large Shareholder, Director at Phaserx Inc. (PZRX), 2017-05-30
- Large Shareholder, Director at Opgen Inc (OPGN), 2016-06-24
- Large Shareholder, Director at Veracyte Inc. (VCYT), 2016-06-21
- Large Shareholder at Flexion Therapeutics Inc (FLXN), 2016-06-11
- Other at Glaukos Corp (GKOS), 2016-06-03
- Director at Immune Design Corp. (IMDZ), 2016-01-07
- Director at Five Prime Therapeutics Inc (FPRX), 2015-06-16
- Large Shareholder at Inogen Inc (INGN), 2015-05-11
- Large Shareholder at Second Sight Medical Products Inc (EYES), 2014-12-03
- Director at Cadence Pharmaceuticals Inc (CADX), 2014-03-21
- Director at Trius Therapeutics Inc (TSRX), 2013-09-13
- Large Shareholder, Director at Helicos Biosciences Corp (HLCS), 2009-09-21
Insider Trading: Purchases See All
| Symbol | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| PZRX | $5.00 | 596,477 | $2,982,385.00 | 1,931,094 | 2016-05-23 | Filing |
| PZRX | $5.00 | 3,523 | $17,615.00 | 11,408 | 2016-05-23 | Filing |
| PZRX | $5.00 | 596,477 | $2,982,385.00 | 1,931,094 | 2016-05-23 | Filing |
| PZRX | $5.00 | 3,523 | $17,615.00 | 11,408 | 2016-05-23 | Filing |
| OPGN,OPGNW | $6.00 | 413,332 | $2,479,992.00 | 485,925 | 2015-05-08 | Filing |
Insider Trading: Sales See All
| Symbol | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| PZRX | $0.01 | 182,914 | $1,829.14 | 1,334,617 | 2016-05-23 | Filing |
| PZRX | $0.01 | 73,615 | $736.15 | 1,517,531 | 2016-05-23 | Filing |
| PZRX | $0.01 | 1,080 | $10.80 | 7,885 | 2016-05-23 | Filing |
| PZRX | $0.01 | 435 | $4.35 | 8,965 | 2016-05-23 | Filing |
| PZRX | $0.01 | 182,914 | $1,829.14 | 1,334,617 | 2016-05-23 | Filing |